Do analysts prefer OBSV or CANF?

Can-Fite BioPharma has a consensus price target of $42.50, suggesting a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is OBSV or CANF more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Can-Fite BioPharma N/A N/A N/A

Do analysts recommend CANF or CURX?

Can-Fite BioPharma currently has a consensus target price of $42.50, indicating a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Can-Fite BioPharma is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CANF or CURX more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Curanex Pharmaceuticals N/A -85.41% -82.11%

Does the media refer more to CANF or CURX?

In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 3 articles in the media. Curanex Pharmaceuticals' average media sentiment score of 0.47 beat Can-Fite BioPharma's score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Curanex Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CANF or NKGN?

Can-Fite BioPharma currently has a consensus target price of $42.50, suggesting a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CANF or NKGN more profitable?

Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A NKGen Biotech N/A N/A -479.36%

Is ATON or CANF more profitable?

Company Net Margins Return on Equity Return on Assets Portage Biotech N/A N/A N/A Can-Fite BioPharma N/A N/A N/A

Does the media favor ATON or CANF?

In the previous week, Can-Fite BioPharma had 2 more articles in the media than Portage Biotech. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 1 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HCWB or CANF?

In the previous week, HCW Biologics had 7 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 10 mentions for HCW Biologics and 3 mentions for Can-Fite BioPharma. HCW Biologics' average media sentiment score of 0.57 beat Can-Fite BioPharma's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Can-Fite BioPharma (CANF) Competitors

$2.97 +0.05 (+1.71%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$2.84 -0.14 (-4.55%)

As of 04:41 AM Eastern

Compare

CANF vs. OBSV, CURX, NKGN, ATON, and HCWB

Should you buy Can-Fite BioPharma stock or one of its competitors? MarketBeat compares Can-Fite BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Can-Fite BioPharma include ObsEva (OBSV), Curanex Pharmaceuticals (CURX), NKGen Biotech (NKGN), Portage Biotech (ATON), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry.

How does Can-Fite BioPharma compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Can-Fite BioPharma has higher revenue and earnings than ObsEva. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Can-Fite BioPharma	$405K	4.80	-$7.63M	-$35.80	N/A

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Can-Fite BioPharma	N/A	N/A	N/A

ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Can-Fite BioPharma has a consensus price target of $42.50, suggesting a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Can-Fite BioPharma had 3 more articles in the media than ObsEva. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Can-Fite BioPharma	Neutral

17.5% of ObsEva shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Can-Fite BioPharma beats ObsEva on 10 of the 13 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Curanex Pharmaceuticals?

Can-Fite BioPharma (NYSE:CANF) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Can-Fite BioPharma's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 3 articles in the media. Curanex Pharmaceuticals' average media sentiment score of 0.47 beat Can-Fite BioPharma's score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curanex Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Curanex Pharmaceuticals has lower revenue, but higher earnings than Can-Fite BioPharma. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	4.80	-$7.63M	-$35.80	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Can-Fite BioPharma currently has a consensus target price of $42.50, indicating a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Can-Fite BioPharma is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Can-Fite BioPharma beats Curanex Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Can-Fite BioPharma compare to NKGen Biotech?

Can-Fite BioPharma (NYSE:CANF) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
NKGen Biotech	N/A	N/A	-479.36%

In the previous week, Can-Fite BioPharma had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for NKGen Biotech. Can-Fite BioPharma's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
NKGen Biotech	Neutral

Can-Fite BioPharma has higher revenue and earnings than NKGen Biotech. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	4.80	-$7.63M	-$35.80	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

Can-Fite BioPharma currently has a consensus target price of $42.50, suggesting a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Can-Fite BioPharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Can-Fite BioPharma beats NKGen Biotech on 8 of the 12 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Portage Biotech?

Portage Biotech (NASDAQ:ATON) and Can-Fite BioPharma (NYSE:CANF) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Can-Fite BioPharma	N/A	N/A	N/A

In the previous week, Can-Fite BioPharma had 2 more articles in the media than Portage Biotech. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 1 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Portage Biotech has higher earnings, but lower revenue than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A
Can-Fite BioPharma	$405K	4.80	-$7.63M	-$35.80	N/A

13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Portage Biotech presently has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Can-Fite BioPharma has a consensus target price of $42.50, suggesting a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Portage Biotech has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Summary

Can-Fite BioPharma beats Portage Biotech on 8 of the 11 factors compared between the two stocks.

How does Can-Fite BioPharma compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Can-Fite BioPharma has higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	714.57	-$7.96M	-$9.46	N/A
Can-Fite BioPharma	$405K	4.80	-$7.63M	-$35.80	N/A

HCW Biologics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

In the previous week, HCW Biologics had 7 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 10 mentions for HCW Biologics and 3 mentions for Can-Fite BioPharma. HCW Biologics' average media sentiment score of 0.57 beat Can-Fite BioPharma's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Can-Fite BioPharma has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Can-Fite BioPharma's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Can-Fite BioPharma	N/A	N/A	N/A

HCW Biologics currently has a consensus price target of $30.00, indicating a potential upside of 501.20%. Can-Fite BioPharma has a consensus price target of $42.50, indicating a potential upside of 1,330.98%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Can-Fite BioPharma beats HCW Biologics on 9 of the 16 factors compared between the two stocks.

Get Can-Fite BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CANF vs. The Competition

Export

Metric	Can-Fite BioPharma	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$1.95M	$1.00B	$7.07B	$23.41B
Dividend Yield	N/A	4.84%	2.66%	4.07%
P/E Ratio	-1.66	1.47	27.25	31.92
Price / Sales	4.80	118.59	543.53	21.80
Price / Cash	N/A	20.06	48.53	25.04
Price / Book	1.69	8.12	10.93	4.80
Net Income	-$7.63M	-$3.83M	$3.57B	$1.07B
7 Day Performance	-0.67%	2.80%	2.31%	1.35%
1 Month Performance	-7.96%	1.71%	1.39%	0.57%
1 Year Performance	-85.72%	50.48%	36.73%	22.01%

Can-Fite BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CANF Can-Fite BioPharma	1.7805 of 5 stars	$2.97 +1.7%	$42.50 +1,331.0%	-85.9%	$1.95M	$405K	N/A	8	Gap Down
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50	Gap Down
CURX Curanex Pharmaceuticals	0.6227 of 5 stars	$0.27 -1.3%	N/A	N/A	$7.87M	N/A	N/A	N/A	News Coverage
NKGN NKGen Biotech	N/A	$0.06 flat	N/A	-81.8%	$7.84M	N/A	N/A	N/A
ATON Portage Biotech	1.0848 of 5 stars	$0.33 +3.8%	$2.00 +502.4%	N/A	$7.78M	N/A	N/A	6	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CANF) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Can-Fite BioPharma (CANF) Competitors

CANF vs. OBSV, CURX, NKGN, ATON, and HCWB

How does Can-Fite BioPharma compare to ObsEva?

Summary

How does Can-Fite BioPharma compare to Curanex Pharmaceuticals?

Summary

How does Can-Fite BioPharma compare to NKGen Biotech?

Summary

How does Can-Fite BioPharma compare to Portage Biotech?

Summary

How does Can-Fite BioPharma compare to HCW Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF vs. The Competition

Can-Fite BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Can-Fite BioPharma (CANF) Competitors

CANF vs. OBSV, CURX, NKGN, ATON, and HCWB

How does Can-Fite BioPharma compare to ObsEva?

Which has preferable earnings & valuation, OBSV or CANF?

Is OBSV or CANF more profitable?

Which has more volatility & risk, OBSV or CANF?

Do analysts prefer OBSV or CANF?

Does the media favor OBSV or CANF?

Do institutionals & insiders have more ownership in OBSV or CANF?

Summary

How does Can-Fite BioPharma compare to Curanex Pharmaceuticals?

Do institutionals and insiders believe in CANF or CURX?

Is CANF or CURX more profitable?

Does the media refer more to CANF or CURX?

Which has higher earnings and valuation, CANF or CURX?

Do analysts recommend CANF or CURX?

Summary

How does Can-Fite BioPharma compare to NKGen Biotech?

Is CANF or NKGN more profitable?

Does the media refer more to CANF or NKGN?

Which has stronger earnings & valuation, CANF or NKGN?

Do analysts prefer CANF or NKGN?

Which has more risk & volatility, CANF or NKGN?

Do institutionals and insiders have more ownership in CANF or NKGN?

Summary

How does Can-Fite BioPharma compare to Portage Biotech?

Is ATON or CANF more profitable?

Does the media favor ATON or CANF?

Which has stronger earnings & valuation, ATON or CANF?

Do institutionals & insiders have more ownership in ATON or CANF?

Do analysts prefer ATON or CANF?

Which has more volatility & risk, ATON or CANF?

Summary

How does Can-Fite BioPharma compare to HCW Biologics?

Which has higher valuation & earnings, HCWB or CANF?

Which has more risk & volatility, HCWB or CANF?

Does the media favor HCWB or CANF?

Do insiders & institutionals believe in HCWB or CANF?

Is HCWB or CANF more profitable?

Do analysts recommend HCWB or CANF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF vs. The Competition

Can-Fite BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools